Search Results - "James Renfroe"

Ataluren treatment of patients with nonsense mutation dystrophinopathy by Bushby, Katharine, Finkel, Richard, Wong, Brenda, Barohn, Richard, Campbell, Craig, Comi, Giacomo P., Connolly, Anne M., Day, John W., Flanigan, Kevin M., Goemans, Nathalie, Jones, Kristi J., Mercuri, Eugenio, Quinlivan, Ros, Renfroe, James B., Russman, Barry, Ryan, Monique M., Tulinius, Mar, Voit, Thomas, Moore, Steven A., Lee Sweeney, H., Abresch, Richard T., Coleman, Kim L., Eagle, Michelle, Florence, Julaine, Gappmaier, Eduard, Glanzman, Allan M., Henricson, Erik, Barth, Jay, Elfring, Gary L., Reha, Allen, Spiegel, Robert J., O'donnell, Michael W., Peltz, Stuart W., Mcdonald, Craig M.

“…ABSTRACT Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable…”
Get full text

Growth and survival of northern leopard frog (Rana pipiens) tadpoles exposed to two common pesticides by Shenoy, Kausalya, Cunningham, B. Thomas, Enfroe, James W.R, Crowley, Philip H

“…Aquatic pollution is an important factor implicated in global amphibian declines. Often amphibians are exposed to sublethal levels of agrochemicals…”
Get full text

Impact of delayed prescription fill on readmission rates for chronic obstructive pulmonary disease and heart failure by Kovacik, Aaron, Bell, Paula C., King, Sean, Mallon, Amy, Renfroe, James, Dyer, Charles

“…In an effort to reduce reimbursement penalty from the Centers for Medicare & Medicaid Services, hospitals have looked to evaluate the effectiveness of existing…”
Get full text

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial by Jagannathan, Prasanna, Giganti, Mark J., Hughes, Michael D., Moser, Carlee, Main, Mark J., Monk, Phillip D., Javan, Arzhang Cyrus, Fletcher, Courtney V., McCarthy, Caitlyn, Wohl, David A., Daar, Eric S., Eron, Joseph J., Singh, Upinder, Smith, Davey M., Fischer, William, Chew, Kara, Smith, David (Davey), Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Javan, Arzhang Cyrus, Moser, Carlee, Giganti, Mark, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Gapara, Morgan, Shahkolahi, Akbar, Main, Mark J., Pierone, Gerald, Elliott, Juliana, Jacobson, Jeffrey, Hojat, Leila, Pasternak, Julie, Berardi, Jonathan, Arar, Celine, Bukhman, Yevgeniy, Jain, Manish, Bukhman, Eugene, Shaik, Sadia, Hatlen, Timothy, Dooley, Kelly, Wilkins, Adaliah, Pérez, Jose, Fernández, Heriberto, Hoover, Keila, Renfroe, James, Weldon, Mauney, Bougher, Genei, Malvestutto, Carlos, Harber, Heather, Cicarella, Robyn, Neytman, Gene, Herman, Jack, Herman, Craig, Swiatek, Joan, Pathak, Divya, Choudhary, Madhu, Sullivano, Jennifer, Torna, Odelsey, Khodabakhshian, Aleen, Benson, Constance, Hendrickx, Steven, Luetkemeyer, Anne, Dentoni-Lasofsky, Dennis, Spikes, Leslie, Hall, Chase, Oakes, Jonathan, Loftis, Amy James, Tebas, Pablo, Short, William, McGuffin, Sarah, Jonsson, Chris, Presti, Rachel, Haile, Alem

“…With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel…”
Get full text

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data by Renfroe, James Benjamin, Isojarvi, Jouko, Lee, Deborah

Get full text